SCHEMBL1712013

SCHEMBL1712013

CC(C)(C)OC(=O)NC[C@@H]1Cn2c(=O)ccc3nccc1c32

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACACB O00763 4/20 0.39
ACACA Q13085 3/20 0.39
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
CCRL2 O00421 1/20 0.35
PBK Q96KB5 1/20 0.35
SPR P35270 1/20 0.34
DRD2 P14416 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
NAMPT P43490 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
BRD4 O60885 1/20 0.33
ENPP2 Q13822 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1712152 1.00 ACACB (0.39) ACACBACACACKS1BSKP1SKP2
SCHEMBL1712214 0.84 HTR1A (0.41) ACACBACACACKS1BSKP1SKP2
SCHEMBL1712022 0.82 JAK1 (0.38) JAK2JAK1
SCHEMBL1711984 0.82 JAK1 (0.38) JAK2JAK1
SCHEMBL13315097 0.81 JAK1 (0.43) CKS1BSKP1SKP2DRD2JAK2
SCHEMBL1712667 0.81 KCNH2 (0.42) ACACBACACACKS1BSKP1SKP2
SCHEMBL14837497 0.81 RORC (0.40) ACACBACACA
SCHEMBL1712080 0.76 JAK2 (0.32) JAK2JAK1
SCHEMBL1724100 0.76 GSK3B (0.33)
SCHEMBL14837465 0.74 CKS1B (0.39) ACACBACACACKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822114-B2 Tricyclic oxazolidinone antibiotic compounds IDORSIA PHARMACEUTICALS LTD (CH) 2017-11-21 US disclosed
US-20160237088-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS IDORSIA PHARMACEUTICALS LTD (CH) 2016-08-18 US disclosed
US-9346804-B2 Tricyclic oxazolidinone antibiotic compounds ACTELION PHARMACEUTICALS LTD. (CH) 2016-05-24 US disclosed
EP-2344495-B1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2014-12-31 EP disclosed
US-20140142093-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2014-05-22 US disclosed
US-8618092-B2 Tricyclic oxazolidinone antibiotic compounds ACTELION PHARMACEUTICALS LTD. (CH) 2013-12-31 US disclosed
US-20110195961-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-11 US disclosed
EP-2344495-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2011-07-20 EP disclosed
WO-2010041194-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195961-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS HRH3, OXA1L, HRH1 ACACB 3938/4885ACACA 3750/4885CKS1B 650/4885
US-20160237088-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS H1-3, HRH3, HRH4 ACACB 3800/4885ACACA 3876/4885CKS1B 910/4885
US-20140142093-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS OXA1L, H1-3, NGLY1 ACACB 4114/4885ACACA 4028/4885CKS1B 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.